中国药房2017，Vol.28Issue(23)：3180-3182,3.DOI:10.6039/j.issn.1001-0408.2017.23.03
老年社区获得性肺炎两种药物治疗方案的最小成本分析
Minimum Cost Analysis of 2 Therapy Plans for Elderly Community Acquired Pneumonia
摘要
Abstract
OBJECTIVE:To compare clinical efficacy,ADR and cost of moxifloxacin alone vs. piperacillin/tazobactam com-bined with azithromycin in the treatment of elderly community acquired pneumonia(CAP). METHODS:In retrospective study, 60 elderly CAP patients were selected from respiratory department of a third grade Class A hospital during Oct. 2015-Apr. 2016, and then divided into group A,B with 30 cases in each group according to the medication regimen. Group A was given Moxifloxa-cin hydrochloride and sodium chloride injection 250 mL,ivgtt,qd;group B was given Azithromycin latobionate for injection 0.50 g,ivgtt,qd+Piperacillin sodium and tazobactam sodium for injection 3.375 g,ivgtt,q8 h. Both groups were treated for 10 d. Clini-cal efficacy,bacteriological efficacy and the occurrence of ADR were compared between 2 groups. The economics of 2 therapy plans were evaluated. RESULTS:Total response rates of group A and B were 90.00% and 93.33%;bacterial clearance rates were 85.00% and 86.36%;the incidence of ADR were 3.33% and 6.67%,without statistical significance(P>0.05). Minimum cost analysis was adopted for economic evaluation;treatment cost of group A was 16646.51 yuan,and that of group B was 19605.74 yuan;the cost of group A was lower than group B. The results of minimum cost analysis were supported by sensitivity analysis. CONCLUSIONS:For empiric treatment of antibiotics in elderly CAP patients,moxifloxacin alone should be the first choice. The therapy plan is effective,low-cost and safe.关键词
社区获得性肺炎/老年患者/莫西沙星/哌拉西林他唑巴坦/阿奇霉素/最小成本分析/药物经济学Key words
Community acquired pneumonia/Elderly patient/Moxifloxacin/Piperacillin/tazobactam/Azithromycin/Mini-mum cost analysis/Pharmacoeconomics分类
医药卫生引用本文复制引用
张莉,张扬,王云飞,王义俊..老年社区获得性肺炎两种药物治疗方案的最小成本分析[J].中国药房,2017,28(23):3180-3182,3.基金项目
江苏省药学会-奥赛康医院药学基金立项课题(No.201504) （No.201504）
